Maraviroc and Vimseltinib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Maraviroc
Vimseltinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased risk of P-gp substrate exposure
Interaction Deep Dive
Avoid concomitant use of vimseltinib with P-gp substrates, as it may increase P-gp substrate exposure. If concomitant use cannot be avoided, take vimseltinib at least 4 hours prior to P-gp substrates1.
Why it happens (mechanism)
Inhibition of P-gp-mediated efflux transport by vimseltinib
Literature reports
1 report — tap to read
a) In a drug interaction study, dabigatran (a P-gp substrate) AUC (0 to inf) and Cmax are predicted to inf increase 2- to 3-fold with concomitant use with vimseltinib 30 mg twice weekly. Dabigatran Cmax and AUC (0 to inf) are predicted to increase up to 1.3-fold if administered 4 hours -inf after administration of vimseltinib 30 mg twice weekly 1.
Common questions
Can I take Maraviroc and Vimseltinib together?
Increased risk of P-gp substrate exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Maraviroc and Vimseltinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Maraviroc or Vimseltinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ROMVIMZA(TM) oral capsules, vimseltinib oral capsules. Deciphera Pharmaceuticals, LLC (per FDA), Waltham, MA, 2025. DailyMed
Keep reading about Maraviroc
Keep reading about Vimseltinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist